Navigating the Radiopharmaceuticals in Nuclear Medicine Market: In-Depth Industry Analysis, Size, Share, and Growth Trends Explored

Market Overview:

Radiopharmaceuticals are radioactive compounds used as tracers in medical imaging and therapeutic procedures. They help clinicians diagnose and treat various medical conditions like cancer, cardiovascular diseases, neurological disorders, and other abnormalities within the body.

Market Dynamics:

The radiopharmaceuticals in nuclear medicine market is expected to grow significantly during the forecast period owing to the rising prevalence of cancer and increasing application of nuclear medicine in disease diagnosis and treatment. According to the International Agency for Research on Cancer (IARC), cancer burden is estimated to reach 29.5 million new cancer cases and 16.3 million cancer deaths by 2040. Nuclear medicine plays a key role in cancer diagnosis and treatment monitoring. Positron emission tomography (PET) scans using radiopharmaceuticals are widely used for cancer screening and staging. Further, growth in geriatric population, which is more prone to developing cancer and neurodegenerative diseases, is also expected to drive the demand for nuclear medicine examinations and radiotracers.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/70

Driver: Growing prevalence of cancer and cardiovascular diseases

The rising incidence of various types of cancer and cardiovascular diseases is one of the major drivers of the radiopharmaceuticals in nuclear medicine market. According to the World Health Organization, cancer is one of the leading causes of death worldwide, accounting for nearly 10 million deaths in 2020. Heart diseases also remain the number one cause of death globally. Nuclear medicine procedures play a crucial role in the diagnosis and treatment of various cancers as well as cardiovascular conditions. Positron emission tomography (PET) scans using radiopharmaceuticals help detect tumors and assess their spread in the body. Radiopharmaceuticals are also used for myocardial perfusion imaging (MPI) scans to evaluate blood flow to the heart muscle at rest and during exercise or pharmacologic stress. The growing demand for early and accurate diagnosis as well as effective management of these life-threatening diseases is considerably driving the demand for nuclear medicine imaging modalities and associated radiopharmaceuticals.

Driver: Increasing applications of innovative radiotracers

Another key driver has been the growing applications of innovative new radiotracers in the diagnosis and treatment monitoring of an expanding range of diseases. Molecular imaging tracers produced using radiopharmaceuticals have enabled early and precise visualization of biological processes at the cellular and molecular levels. Radiotracers targeting unique biomarkers for diseases are augmenting the role of nuclear medicine in diagnosing conditions like Alzheimer's disease, inflammation, and infection imaging among others. Positron emission tomography (PET) combined with novel targeted radiotracers is also finding significant applications in therapy response monitoring and assessing treatment effectiveness in cancer. The continuous research efforts to develop targeted radiotracers have expanded the scope of indications that nuclear medicine can address. This, along with the objective information they provide, is fueling the increased uptake of innovative radiotracers in clinical settings. This rising demand and adoption of versatile novel radiotracers present potential growth opportunities for participants in the radiopharmaceuticals market.

Restrain: Short half-life of radiopharmaceuticals

The short half-life of radiopharmaceuticals, which is usually only a few hours, acts as a major challenge in the radiopharmaceuticals in nuclear medicine market. Most radiopharmaceuticals have half-lives ranging from a few minutes to only a few hours, owing to the radioactive isotopes used in their production. This restricts their distribution radius from the production site and necessitates just-in-time delivery. It also means that radiopharmaceuticals cannot be produced and stocked in bulk as they would decay very quickly. Their short shelf life requires robust supply chain and logistics to transport them from manufacturing facilities to healthcare facilities within their half-lives. Any delays or issues during transportation and delivery can lead to decay of doses, affecting clinical procedures. Moreover, the low half-lives increase production and handling complexities and costs. Overcoming these limitations associated with short radioisotope half-life remains a key restraint area impacting the radiopharmaceuticals market.

Opportunity: Expanding applications of theranostics

The field of theranostics, which synergistically combines therapy and diagnostic capabilities, provides lucrative opportunities for growth in the radiopharmaceuticals market. Theranostic radiopharmaceuticals allow monitoring treatment response through integrated diagnosis and therapy using the same compound. This novel approach is helping expand the applications of radiopharmaceuticals beyond diagnostic uses. For instance, radiolabeled antibodies, peptides and other ligands that can selectively target tumor cells are being evaluated for both diagnostic imaging and targeted radionuclide therapy of cancer. This helps optimize individual treatment planning using personalized dosimetry estimates from diagnostic scans. Several theranostic pairs targeting prostate cancer, neuroendocrine tumors and other cancers are in development and clinical trials. As theranostics enables more effective and personalized management of diseases, its increasing adoption presents significant commercial opportunities for innovators in the radiopharmaceuticals domain. Continuous research and newer combination products will further contribute to the promise shown by this evolving field.

List of TOP Players in Market Report are: -

◘ Progenics Pharmaceuticals Inc.
◘ NorthStar Medical Radioisotopes LLC
◘ Curium Pharma
◘ Life Molecular Imaging
◘ Lantheus Holdings Inc.
◘ Cardinal Health Inc.
◘ General Electric Company
◘ Bracco S.p.A.
◘ Bayer AG
◘ Advanced Accelerator Applications
◘ S.A.
◘ Eli Lilly and Company
◘ Nihon Medi-Physics. Co. Ltd.
◘ FUJIFILM Toyama Chemical Co., Ltd.,
◘ Jubilant Life Sciences Ltd.
◘ Samyoung Unitech
◘ DuChemBio Inc.

𝐍𝐨𝐭𝐞: 𝐌𝐚𝐣𝐨𝐫 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐚𝐫𝐞 𝐬𝐨𝐫𝐭𝐞𝐝 𝐢𝐧 𝐧𝐨 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫 𝐨𝐫𝐝𝐞𝐫.

Furthermore, the years considered for the study are as follows:

Historical data - 2016-2021
The base year for estimation - is 2021
Estimated Year - 2023
Forecast period** - 2023 to 2030

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/70

This Radiopharmaceuticals in Nuclear Medicine Market Research/Analysis Report Contains Answers to your following Questions:

◈What are the current global trends in the Radiopharmaceuticals in Nuclear Medicine market, and will the market experience an increase or decrease in demand in the upcoming years?

◈ What is the expected demand for various product types within the Radiopharmaceuticals in Nuclear Medicine market, and what are the emerging Market applications and trends?

◈ What are the projections for the global Radiopharmaceuticals in Nuclear Medicine Market in terms of capacity, production, production value, cost, profit, market share, supply, consumption, import, and export?

◈ How will strategic developments shape the Market trajectory in the medium to long term?

◈ What factors contribute to the final price of Radiopharmaceuticals in Nuclear Medicine , and what are the raw materials used in its manufacturing?

◈ What is the market's growth potential, particularly with the increasing adoption of Radiopharmaceuticals in Nuclear Medicine in mining?

◈ What is the current and 2022 value of the global market, and who are the leading companies in this market?

◈ What recent Market trends can be leveraged to create additional revenue streams?

◈ What entry strategies, economic impact mitigation measures, and marketing channels should be considered for the Radiopharmaceuticals in Nuclear Medicine Market?

Summarized Extracts from TOC of Market Study

Chapter 1 Radiopharmaceuticals in Nuclear Medicine Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of Radiopharmaceuticals in Nuclear Medicine

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the Radiopharmaceuticals in Nuclear Medicine industry

1.4 Methodology of The Study

1.5 Research Data Source

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Market, by Type

Chapter 5 Market, by Application

Chapter 6 Market Analysis by Regions

Chapter 7 North America Market Analysis by Countries

Chapter 8 Europe Radiopharmaceuticals in Nuclear Medicine Market Analysis by Countries

Chapter 9 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Analysis by Countries

Chapter 10 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Analysis by Countries

Chapter 11 South America Radiopharmaceuticals in Nuclear Medicine Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Market Forecast

Chapter 15 New Project Feasibility Analysis

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.